igf-1 lr3 guide Dosage: What to Know About Dosing, Safety, and Clinical Use IGF 1 / LR 3

Krantz E, Caidahl K, Andersson B, Bjarnason R, Eden S, Johannsson G

The timeframes described represent general expectations based on clinical experience, but individual responses may occur more rapidly or require longer durations to achieve desired outcomes

Rapid Absorption: Facilitates quicker absorption through mucosal membranes, potentially leading to faster onset of action

IGF-1 LR3 and PEG-MGF are listed on the World Anti-Doping Agency (WADA) Prohibited List under category S2 (peptide hormones, growth factors, and related substances), making them prohibited year-round for athletes subject to anti-doping testing